Healthcare Industry News: Leksell Gamma Knife
News Release - March 1, 2006
IMPAC Announces Group Purchasing Agreement With Consorta, Inc.; Consorta Membership to Receive Full Benefit of Leading Oncology IT SolutionMOUNTAIN VIEW, Calif., March 1 (HSMN NewsFeed) -- IMPAC Medical Systems, Inc., part of the Elekta Group and a leading provider of information technology (IT) solutions for oncology care, joins the radiation oncology agreement between Elekta and Consorta. Consorta Inc., is a health care group purchasing organization that delivers high-quality, cost-effective products and services to its members including more than 2,100 acute and non-acute care facilities. Consorta members will now have greater access to IMPAC's comprehensive healthcare IT solution that includes an electronic medical record (EMR) designed specifically for oncology, and full-featured practice management capability.
The addition of IMPAC enhances Consorta's existing relationship with Elekta, whose contract originated in May 2004 and includes the revolutionary Elekta Synergy® treatment delivery series. Consorta also has an agreement with Elekta for PrecisePlan® treatment planning systems stereotactic neurosurgical and radiosurgery products, including Leksell Gamma Knife®. With the addition of IMPAC to the Elekta contract, all of Consorta's current and future radiation oncology equipment will fully support EMR-based image-guided radiotherapy (IGRT), thereby providing optimized clinical workflow processing and a central repository for oncology data and images. Additional fully integrated features, such as department scheduling, on and off line transcription, automated procedure capture and audit, medical billing and A/R, and management reporting, provide a comprehensive process management solution for the entire cancer care team -- whether in one location or in multiple sites.
"IMPAC's open architecture and flexibility bring great value to Consorta members who operate not only Elekta Oncology products but all other manufacturers as well. The ability to use as many or as few of the IMPAC components gives our members the value and flexibility they need. We are very pleased to offer this comprehensive management solution to our membership," said Dan Ingram, Director of Imaging Services for Consorta.
While Consorta customers will take advantage of IMPAC's vendor-independent support for radiation therapy delivery, the new joint IMPAC/Elekta agreement does ensure added value for members who opt for a combined solution. IMPAC's best-of-breed oncology EMR combined with Elekta's clinically-proven IGRT technology, results in the most streamlined image-guided treatment management (IGTM(TM)) solution currently available.
"We are extremely excited to have entered into an agreement with Consorta," states James Hoey, President and CEO, IMPAC Medical Systems Inc. "This partnership assures that members of Consorta, will have immediate access to IMPAC's wide breadth of IT solutions that not only preserves the value of their installed treatment and planning equipment investment, but also takes complete advantage of Elekta's new IGRT equipment. Together this platform comprises the most advanced, comprehensive solution for radiation therapy available in the industry."
For more information, please contact:
Lorna Murdock, Marketing Communications Manager
IMPAC Medical Systems, Inc.
Tel: 650-623-8937, e-mail: email@example.com
Kim R. Auerbach, National Accounts Manager, IMPAC Medical Systems, Inc.,
Tel: 650-623-3864, e-mail: firstname.lastname@example.org
International: Peter Ejemyr, Group VP Corporate Communications,
Tel: +46 733 611 000, e-mail: email@example.com
United States: Lars Jonsteg, VP Investor Relations North America,
Tel: +46 708-783 735, e-mail: firstname.lastname@example.org
Dan Ingram, Director, Imaging Services, Consorta Inc.
Tel: 847-592-7852, e-mail: email@example.com
About IMPAC Medical Systems
IMPAC Medical Systems, Inc., a company in the Elekta Group, provides healthcare IT solutions that streamline clinical and business operations across the spectrum of cancer care. IMPAC's open integration to multiple healthcare data and imaging systems offers oncology-specific patient charting and practice management, as well as best-of-breed systems for anatomic pathology, clinical laboratory, and cancer registry. With products that range from diagnosis and treatment through long-term follow-up, IMPAC provides a comprehensive oncology management solution that helps improve overall communication, process efficiency, and quality patient care. For more information about IMPAC's products or services, please call 888-GO-IMPAC or visit www.impac.com.
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective. With approx. 1700 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta's products or services, please visit www.elekta.com.
Consorta, Inc. is a leading health care resource management and group purchasing organization, whose shareholders are faith based or non-profit health systems. As a cooperative, Consorta's shareholders and participants share fully in the organization's bottom-line performance and receive discounts on product purchases through scale purchasing economies. Consorta's shareholders are among the leading integrators of non-profit health care in America, sponsoring significant care providers in many parts of the country. Consorta's shareholder health care systems operate more than half of all Catholic hospitals in the United States, own many extended and alternate care sites and have extensive affiliate relationships with other non-profit hospitals and alternate care facilities.
Source: IMPAC Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.